These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36802403)

  • 1. Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy.
    Becker JN; Hermann R; Wichmann J; Sonnhoff M; Christiansen H; Bruns F
    PLoS One; 2023; 18(2):e0282015. PubMed ID: 36802403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Chargi N; Bashiri F; Wendrich AW; Smid EJ; de Jong PA; Huitema ADR; Devriese LA; de Bree R
    Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3685-3694. PubMed ID: 35038029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
    Schaeffers AWMA; Devriese LA; van Gils CH; Dankbaar JW; Voortman J; de Boer JP; Slingerland M; Hendriks MP; Smid EJ; Frederix GWJ; de Bree R
    PLoS One; 2023; 18(11):e0294147. PubMed ID: 38011186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin
    Nassif S; Wichmann J; Strube D; Vassis S; Christiansen H; Steinmann D
    In Vivo; 2022; 36(2):821-832. PubMed ID: 35241538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.
    Liu W; Qdaisat A; Ferrarotto R; Fuller CD; Guo M; Meyer LA; Narayanan S; Lopez G; Cohen L; Bruera E; Hanna EY; Yeung SJ
    Cancer; 2021 Feb; 127(4):528-534. PubMed ID: 33085092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.
    Boardman CH; Brady WE; Dizon DS; Kunos CA; Moore KN; Zanotti KM; Matthews C; Cosin JA; Aghajanian C; Fracasso PM
    Gynecol Oncol; 2018 Nov; 151(2):202-207. PubMed ID: 30174176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
    Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
    Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
    Vlacich G; Diaz R; Thorpe SW; Murphy BA; Kirby W; Sinard RJ; Shakhtour B; Shyr Y; Murphy P; Netterville JL; Yarbrough WG; Cmelak AJ
    Oncologist; 2012; 17(5):673-81. PubMed ID: 22550060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
    Bril SI; Al-Mamgani A; Chargi N; Remeijer P; Devriese LA; de Boer JP; de Bree R
    Head Neck; 2022 Jan; 44(1):189-200. PubMed ID: 34713519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
    Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
    Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S; Takahashi R; Isohashi F; Yokoi T; Ito K; Tsutui T; Ogata T; Yoshioka Y; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Sep; 23(7):1279-86. PubMed ID: 23835505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
    Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
    Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma in Japanese women.
    Umayahara K; Takeshima N; Nose T; Fujiwara K; Sugiyama Y; Utsugi K; Yamashita T; Takizawa K
    Int J Gynecol Cancer; 2009 May; 19(4):723-7. PubMed ID: 19509578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer.
    Alamgeer M; Coleman A; McDowell L; Giddings C; Safdar A; Sigston E; Wang Y; Subramaniam A
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1674. PubMed ID: 35792145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
    Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
    Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.